NDAORALTABLET, DELAYED RELEASE
Approved
Jun 2019
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
5/8 — Partial
THIOLA EC (tiopronin) by Mission Pharmacal is cystine disulfide reduction [moa]. Approved for reducing and complexing thiol [epc]. First approved in 2019.
Drug data last refreshed 21h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
THIOLA EC (tiopronin) is an oral delayed-release tablet that reduces cystine disulfide through a reducing and complexing thiol mechanism of action. It is indicated for patients requiring cystine reduction therapy, primarily those with cystinuria. The drug works by converting harmful cystine into more soluble compounds, reducing kidney stone formation and related complications.
$23MPart D
PeakStable
12.1 years to LOEProduct is at peak sales phase with stable commercial performance; brand team is focused on maintaining market position in a niche indication with limited patient population.
Mechanism of Action
Cystine Disulfide Reduction
Pharmacologic Class:
Reducing and Complexing Thiol
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Career opportunities on THIOLA EC are concentrated in operations, manufacturing, and technical support roles rather than commercial or medical affairs functions. This reflects Mission Pharmacal's focus on production efficiency and quality maintenance for a stable, niche market product.
ELECTRICIANMECHANICAL MAINTENANCE TECHNICIAN I
Worked on THIOLA EC at Mission Pharmacal? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.